Last reviewed · How we verify
insulin aspart + insulin aspart protamin
This is a biphasic insulin formulation combining rapid-acting insulin aspart with intermediate-acting insulin aspart protamine to provide both immediate and sustained blood glucose control.
This is a biphasic insulin formulation combining rapid-acting insulin aspart with intermediate-acting insulin aspart protamine to provide both immediate and sustained blood glucose control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | insulin aspart + insulin aspart protamin |
|---|---|
| Also known as | novomix |
| Sponsor | Steno Diabetes Center Copenhagen |
| Drug class | Insulin (biphasic rapid-acting insulin analog) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells, promoting glucose uptake and lowering blood glucose quickly. The protamine-complexed component provides a longer duration of action, creating a biphasic profile that mimics physiological insulin secretion with both mealtime and basal coverage in a single injection.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: